EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY 4.0

KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer

Noboru Yamamoto, Miyako Satouchi, Toshihiko Doi, Yutaka Fujiwara, Noriko Yanagitani, Yoshitaka Kawa, Kiyotaka Yoh, Lance Leopold, Mihaela Munteanu, Takashi Sawada, Shirong Han, Kazuo Noguchi und 1 weitere

Investigational New Drugs · 2024-06 · 42 (3) · 261-271

DOI: 10.1007/s10637-024-01422-6 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Investigational New Drugs, online erschienen am 26.03.2024. Verfasst von Noboru Yamamoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Therapeutics, National Cancer Center Hospital, 5 Chome-1-1 Tsukiji, Tokyo, Japan. nbryamam@ncc.go.jp. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and Incyte Corporation, Wilmington, DE, U….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pembrolizumab plus epacadostat (indoleamine 2,3-dioxygenase-1 inhibitor) was well tolerated in Japanese patients with advanced solid tumors in part A of the nonrandomized, open-label, phase 1 KEYNOTE-434 study (NCT02862457). We report results from part B, which evaluated epacadostat plus pembrolizumab and chemotherapy in Japanese patients with advanced non–small-cell lung cancer (NSCLC).

Methods

Eligible patients aged ≥ 20 years had histologically or cytologically confirmed stage IIIB or IV NSCLC with no prior systemic therapy, and ECOG performance status of 0 or 1. Patients received epacadostat 100 mg orally twice-daily, pembrolizumab 200 mg intravenously every-3-weeks for ≤ 35 cycles, and 4 cycles of chemotherapy (cohort 1: cisplatin plus pemetrexed, non-squamous; cohort 2: carboplatin plus pemetrexed, non-squamous; cohort 3: carboplatin plus paclitaxel, squamous or non-squamous). Primary endpoint was incidence of dose-limiting toxicities (DLTs). Following unfavorable results from other studies, a protocol amendment removed epacadostat from the treatment combination.

Results

Of 19 patients, 7 were enrolled in cohort 1, and 6 each in cohorts 2 and 3. Median follow-up was 13.7 (range, 4.2–27.8) months. Five of 17 (29%) DLT-evaluable patients experienced ≥ 1 DLT (cohort 1, n = 1; cohorts 2 and 3, n = 2 each); most commonly maculopapular rash (grade 3, n = 3) and increased alanine aminotransferase (grade 2, n = 1; grade 3, n = 2). All patients experienced treatment-related adverse events (AEs); 58% experienced grade 3 or 4 treatment-related AEs. Objective response rate was 47%.

Conclusion

The combination of epacadostat plus pembrolizumab and chemotherapy was found to be tolerable in Japanese patients with advanced NSCLC.

Trial registration

ClinicalTrials.gov , NCT02862457.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedCarboplatinCisplatinEast Asian PeopleJapanOximesPemetrexedSulfonamides

Stichwörter der Autor:innen

Clinical trial, phase 1Indoleamine 2,3-dioxygenaseNon‒small-cell lung cancerPembrolizumab

Substanzen

Antibodies, Monoclonal, HumanizedCarboplatinCisplatinepacadostatOximespembrolizumabPemetrexedSulfonamides

Autor:innen und Institutionen

  • Department of Experimental Therapeutics, National Cancer Center Hospital, 5 Chome-1-1 Tsukiji, Tokyo, Japan. nbryamam@ncc.go.jp.
  • Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan.
  • Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Experimental Therapeutics, National Cancer Center Hospital, 5 Chome-1-1 Tsukiji, Tokyo, Japan.
  • Department of Thoracic Oncology, Aichi Cancer Center, Aichi, Japan.
  • Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Förderung

  • Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and Incyte Corporation, Wilmington, DE, U…

Zitieren

APA

Yamamoto, N., Satouchi, M., Doi, T., Fujiwara, Y., Yanagitani, N., Kawa, Y., Yoh, K., Leopold, L., Munteanu, M., Sawada, T., Han, S., Noguchi, K., & Nishio, M. (2024). KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer. Investigational New Drugs, 42(3), 261-271. https://doi.org/10.1007/s10637-024-01422-6

Vancouver

Yamamoto N, Satouchi M, Doi T, Fujiwara Y, Yanagitani N, Kawa Y, et al. KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer. Investigational New Drugs. 2024;42(3):261-271. doi:10.1007/s10637-024-01422-6

BibTeX
@article{Yamamoto2024,
  author = {Yamamoto, Noboru and Satouchi, Miyako and Doi, Toshihiko and Fujiwara, Yutaka and Yanagitani, Noriko and Kawa, Yoshitaka and Yoh, Kiyotaka and Leopold, Lance and Munteanu, Mihaela and Sawada, Takashi and Han, Shirong and Noguchi, Kazuo and Nishio, Makoto},
  title = {KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer},
  journal = {Investigational New Drugs},
  year = {2024},
  volume = {42},
  number = {3},
  pages = {261--271},
  doi = {10.1007/s10637-024-01422-6}
}
Kostenlos starten →